CEO Interview: Thalia’s RNA Therapeutics Strategy
Thalia Therapeutics plc announced the release of a video interview with its CEO, Dr. David Solomon, detailing the company's strategic shift towards high-value RNA therapeutics and its ongoing development of Nuvec®, a proprietary gene delivery system. The interview highlights Thalia's focus on opportunities within cardiovascular disease and oncology, aiming to address unmet medical needs with its innovative RNA-based treatments and delivery platform.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
Thalia Therapeutics plc (AIM: THAT), a biotech company developing innovative RNA therapeutics, is pleased to announce the release of a new video interview with Chief Executive Officer, Dr David Solomon.
In the interview, Dr Solomon discusses the Company's strategic transition to Thalia Therapeutics, the rationale behind its increasing focus on high-value RNA therapeutics, the continued development of Nuvec®, and the opportunities the Company sees in cardiovascular disease and oncology.
The interview is available to watch via the Company's website at: https://investors.thaliatx.com/activity-updates
| Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer | Via Thalia Investor Hub https://investors.thaliatx.com/link/P4zkAe |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker Guy McDougall | Tel: +44 (0)20 3657 0050 |
| Northstar Communications Investor relations and Communications Sarah Hollins Cohesion Bureau Investor relations and Communications Mary-Ann Chang | Tel: +44 (0)20 7183 2463 Tel: +44 (0)7483 284853 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.